Literature DB >> 32492388

A Sympathetic Treatment for Obesity.

Jung Dae Kim1, Sabrina Diano2.   

Abstract

Amphetamine (AMPH), mainly used in the treatment of attention deficit hyperactivity disorder and narcolepsy, has weight loss properties, although with detrimental cardiovascular effects. In this issue, Mahú et al. (2020) describe the effect of a new derivative of AMPH, "PEGyAMPH," a brain-spared anti-obesity drug that alters sympathetic activity without cardiovascular side effects.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32492388      PMCID： PMC8142296          DOI： 10.1016/j.cmet.2020.05.009

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  8 in total

1.  Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse.

Authors:  R B Rothman; J S Partilla; M H Baumann; C M Dersch; F I Carroll; K C Rice
Journal:  Synapse       Date:  2000-03-01       Impact factor: 2.562

Review 2.  Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review.

Authors:  John R Richards; Timothy E Albertson; Robert W Derlet; Richard A Lange; Kent R Olson; B Zane Horowitz
Journal:  Drug Alcohol Depend       Date:  2015-02-18       Impact factor: 4.492

Review 3.  Mechanisms of neurotransmitter release by amphetamines: a review.

Authors:  David Sulzer; Mark S Sonders; Nathan W Poulsen; Aurelio Galli
Journal:  Prog Neurobiol       Date:  2005-04       Impact factor: 11.685

Review 4.  How addictive drugs disrupt presynaptic dopamine neurotransmission.

Authors:  David Sulzer
Journal:  Neuron       Date:  2011-02-24       Impact factor: 17.173

5.  Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport.

Authors:  D Sulzer; T K Chen; Y Y Lau; H Kristensen; S Rayport; A Ewing
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

6.  Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine.

Authors:  R Kuczenski; D S Segal; A K Cho; W Melega
Journal:  J Neurosci       Date:  1995-02       Impact factor: 6.167

7.  Brain-Sparing Sympathofacilitators Mitigate Obesity without Adverse Cardiovascular Effects.

Authors:  Inês Mahú; Andreia Barateiro; Eva Rial-Pensado; Noelia Martinéz-Sánchez; Sandra H Vaz; Pedro M S D Cal; Benjamin Jenkins; Tiago Rodrigues; Carlos Cordeiro; Miguel F Costa; Raquel Mendes; Elsa Seixas; Mafalda M A Pereira; Nadiya Kubasova; Vitka Gres; Imogen Morris; Carolina Temporão; Marta Olivares; Yolanda Sanz; Albert Koulman; Francisco Corzana; Ana M Sebastião; Miguel López; Gonçalo J L Bernardes; Ana I Domingos
Journal:  Cell Metab       Date:  2020-05-12       Impact factor: 27.287

8.  A brain-sparing diphtheria toxin for chemical genetic ablation of peripheral cell lineages.

Authors:  Mafalda M A Pereira; Inês Mahú; Elsa Seixas; Noelia Martinéz-Sánchez; Nadiya Kubasova; Roksana M Pirzgalska; Paul Cohen; Marcelo O Dietrich; Miguel López; Gonçalo J L Bernardes; Ana I Domingos
Journal:  Nat Commun       Date:  2017-04-03       Impact factor: 14.919
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.